Bionano Genomics, Inc. (BNGO): who owns it and who trades it
As of Nov 16, 2026, BNGO insiders reported 2 purchases worth $9.7K in the last 12 months. The largest buyer was Albert Luderer (CEO), with $9.7K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Bionano Genomics
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, BNGO insiders reported $9.7K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | Albert Luderer | CEO | Purchase | 4,000 | $1.21 | $4.8K | Form 4 |
| Aug 21, 2026 | Albert Luderer | CEO | Purchase | 4,000 | $1.22 | $4.9K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Albert Luderer | Interim Chief Executive, Director | $9.7K | – | Sep 4, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
BNGO short interest
High short interest. 11.8% of BNGO shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 13%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.39M BNGO shares were sold short, 11.8% of the shares outstanding, up 2.0% from the report before. At the average daily volume of 187,812 shares, buying them all back would take about 7.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.39M | 11.78% | +2% | 187,812 | 7.4 |
| Oct 15, 2026 | 1.36M | 11.55% | -33% | 238,309 | 5.7 |
| Sep 30, 2026 | 2.04M | 17.28% | +78% | 978,648 | 2.1 |
| Sep 15, 2026 | 1.14M | 9.72% | -6% | 4.14M | 1.0 |
| Aug 31, 2026 | 1.22M | 10.39% | +6% | 162,135 | 7.5 |
| Aug 14, 2026 | 1.15M | 9.80% | +8% | 133,295 | 8.7 |
| Jul 31, 2026 | 1.07M | 9.61% | -2% | 98,480 | 10.8 |
| Jul 15, 2026 | 1.09M | 9.79% | -6% | 126,946 | 8.6 |
| Jun 30, 2026 | 1.16M | 10.43% | +3% | 140,775 | 8.2 |
| Jun 15, 2026 | 1.13M | 10.17% | +0% | 152,190 | 7.4 |
| May 29, 2026 | 1.12M | 10.12% | -8% | 162,940 | 6.9 |
| May 15, 2026 | 1.22M | 11.03% | +9% | 188,548 | 6.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Bionano Genomics company events
Bionano Genomics filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Sep 14, 2026AnnouncementShared information with investors. Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Jun 24, 2026AnnouncementBionano Genomics, Inc. issued a press release announcing the hiring of Alex Hastie, Ph.D. as the Chief Scientific Officer of the Company effective July 20, 2026, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein. Filing
- Jun 5, 2026LeadershipAlka Chaubey, Ph.D. resigned as Chief Medical Officer of Bionano Genomics, Inc. effective July 5, 2026. Filing
- May 28, 2026AnnouncementBionano Genomics, Inc. announced that it repaid in full all outstanding Senior Secured Convertible Debentures on May 26, 2026, the scheduled maturity date. Filing
- May 14, 2026VoteReported shareholder vote results. Filing
- May 13, 2026ResultsReleased financial results. Filing
- May 6, 2026LeadershipBionano Genomics, Inc. R. Erik Holmlin, Ph.D. was terminated as the Company’s President and Chief Executive Officer, effective immediately. Filing
- Mar 23, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Bionano Genomics financials
Famous investors that hold BNGO
2 of the 50 well-known investors we track reported holding BNGO in their latest 13F filing. The largest position is Jim Simons's, worth $240K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 154,000 | $240K | 0.0% | +201% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 10,905 | $17K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named BNGO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | CVI Investments, Inc. | 13G/A | 9.9% |
| Nov 16, 2026 | CVI Investments, Inc. | 13G/A | 9.9% |
| Oct 19, 2026 | Orin Hirschman | 13G | 9.9% |
| Oct 19, 2026 | Orin Hirschman | 13G | 9.9% |
Questions about Bionano Genomics, Inc. (BNGO) stock
Are BNGO insiders buying or selling?
In the last 12 months, BNGO insiders reported 2 open-market purchases worth $9.7K and no sales. The latest trade was on Sep 4, 2026. See every trade.
What is the short interest in BNGO?
As of Oct 30, 2026, 1.39M BNGO shares were sold short, 11.8% of the shares outstanding, up 2.0% from the report before. At the average daily volume of 187,812 shares, buying them all back would take about 7.4 trading days (days to cover). See the history.
Which famous investors hold BNGO?
2 of the 50 well-known investors we track reported BNGO in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $240K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.